Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNervGen Pharma Corp

NervGen Pharma Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
5.15 CAD 0.00(0%)
Last update at 2026-03-17T13:30:00Z
Market Cap
416.66M

Momentum Score

…

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.15
Low
5.15
High
52 Week Price Range
2.57
Low
8.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.15
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-820.11%
Net Debt
-
ROCE
-964.50%
Diluted EPS TTM
-0.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -24.01M -22.38M -20.72M -12.73M -11.19M
Net income -24.01M -22.38M -20.72M -12.73M -11.19M
Selling general administrative 9.18M 9.63M 6.34M 4.50M 5.03M
Reconciled depreciation 0.08M 0.15M 0.12M 0.04M 0.04M
Ebit - - -23.03M -12.81M -11.20M
Ebitda - - -20.09M -11.33M -11.16M
Operating income -24.93M -17.78M -23.03M -11.38M -11.20M
Interest expense - 0.00M 0.51M 0.00M 0.00M
Interest income 0.81M 0.55M 0.20M 0.03M 0.02M
Net interest income 0.81M 0.55M -0.31M -1.40M 0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 24.93M 17.78M 23.03M 11.38M 11.20M
Total other income expense net 0.11M -5.16M 2.62M 0.06M -0.01M
Net income from continuing ops -24.01M -22.38M -20.72M -12.73M -11.19M
Net income applicable to common shares - - -20.72M -12.73M -11.19M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 19.49M 13.24M 23.88M 17.90M 6.68M
Intangible assets 0.46M 0.52M 0.43M 0.47M 0.47M
Other current assets 0.11M - 0.59M 0.36M 0.49M
Total liab 16.91M 15.25M 10.41M 1.08M 0.76M
Total stockholder equity 2.58M -2.01M 13.46M 16.82M 5.92M
Other current liab 11.86M 11.73M 6.73M 0.27M 0.16M
Common stock - - 57.41M 42.40M 22.95M
Capital stock 81.10M 58.93M 57.41M 42.40M 22.95M
Retained earnings -102.16M -78.15M -55.77M -35.05M -22.32M
Cash 17.27M 11.66M 22.45M 16.93M 5.60M
Total current liabilities 16.90M 15.14M 10.22M 1.08M 0.76M
Other stockholder equity - - 11.82M 9.46M 5.30M
Property plant equipment - - 0.30M 0.00M 0.00M
Total current assets 19.01M 12.52M 23.15M 17.42M 6.20M
Long term investments 0.01M - - - -
Net tangible assets - - 13.03M 16.35M 5.45M
Short term investments 0.10M - - - -
Net receivables - 0.25M 0.03M 0.06M 0.06M
Accounts payable - 0.55M 2.00M 0.35M 0.17M
Non current assets total 0.47M 0.72M 0.73M 0.48M 0.47M
Capital lease obligations 0.11M 0.20M 0.28M - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.06M -0.14M -0.02M -0.05M -0.00M
Change to liabilities - - 2.32M 0.32M -0.17M
Total cashflows from investing activities - - -0.02M -0.05M -0.00M
Net borrowings -0.10M -0.10M -0.08M -0.08M -0.08M
Total cash from financing activities 22.70M 0.77M 22.64M 19.61M 7.85M
Change to operating activities - - -0.24M 0.11M 1.52M
Net income -24.01M -22.38M -20.72M -12.73M -11.19M
Change in cash 5.61M -10.79M 5.52M 11.33M 1.50M
Begin period cash flow 11.66M 22.45M 16.93M 5.60M 4.11M
End period cash flow 17.27M 11.66M 22.45M 16.93M 5.60M
Total cash from operating activities -16.84M -11.30M -17.78M -8.27M -6.30M
Issuance of capital stock 23.01M 0.00M 19.76M 18.90M 8.71M
Depreciation 0.08M 0.15M 0.12M 0.04M 0.04M
Change to account receivables -0.17M -0.22M 0.04M -0.00M 0.06M
Other cashflows from financing activities - - -0.13M -1.67M -1.17M
Change to netincome - - 0.71M 3.98M 3.43M
Capital expenditures 0.00M 0.14M 0.02M 0.00M 0.00M
Change in working capital 0.84M -0.24M 2.11M 0.43M 1.41M
Stock based compensation 5.80M 6.04M 2.77M 4.02M 3.42M
Other non cash items 0.01M 0.01M 0.53M - -
Free cash flow -16.84M -11.44M -17.81M -8.31M -6.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NGEN
NervGen Pharma Corp		 -
-%		 5.15 - - - 189.48 -4.54
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.01
1.96%		 0.50 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 0.01
1.59%		 0.64 - - - 15.17 -58.16

Profile*

NervGen Pharma Corp

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4

778-731-1711

https://www.nervgen.com

Name Title Year Born
Mr. William Joseph Radvak BASc Co-Founder, Interim CEO & Exec. Chairman 1963
Dr. Harold Martin Punnett D.M.D. Co-Founder & Independent Director NA
Mr. William J. Adams C.A., CPA, CA, CPA CFO & Corp. Sec. 1962
Dr. Daniel D. Mikol M.D., Ph.D. Chief Medical Officer NA
Dr. Adam H. Rogers M.D. Interim Pres & Director NA
Mr. Brian McAlister Co-Founder & Advisor NA
Mr. Michael Kelly CEO, President & Director 1966
Mr. William Joseph Radvak BASc Co-Founder & Advisor 1963
Mr. William J. Adams C.A., CPA, CA, CPA CFO & Corporate Secretary 1962
Dr. Charles V. Olson D.Sc. Senior Vice President of Technical Operations 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…